AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Still some way to go...
Upside 240%
Price (€) 3.36
Market Cap (€M) 122
Perf. 1W: -1.03%
Perf. 1M: 1.97%
Perf. 3M: -28.2%
Perf Ytd: 1.97%
10 day relative perf. to stoxx600: 1.13%
20 day relative perf. to stoxx600: 0.68%
EPS change22/05/2020

No major changes after the release of the FY19 report

Change in EPS2019 : € -0.49 vs -0.48ns
2020 : € -0.32 vs -0.34ns

No major changes to our forecasts. The only ones come from the integration of the detailed FY19 numbers which marginally impact our forecasts, with hardly any change to our target price.


17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

31 Mar 21 Earnings/sales releases
FY20 unsuprising; waiting for more

15 Dec 20 Financing issue
A double bond issue

21 Sep 20 Earnings/sales releases
Update on the group's business